---
title: "Novartis Expands Pipeline With $2 Billion Biotech Deal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280810676.md"
description: "Novartis has agreed to acquire U.S.-based biotech company Excellergy for up to $2 billion, aiming to enhance its immunology pipeline, particularly for food allergies. The deal includes upfront and milestone payments and is expected to close in the second half of 2026, pending necessary approvals. This acquisition follows Novartis's recent $3 billion investment in a breast cancer treatment candidate and is part of a broader strategy to expand its portfolio, with a commitment of $23 billion for U.S. research and production facilities."
datetime: "2026-03-27T14:29:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280810676.md)
  - [en](https://longbridge.com/en/news/280810676.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280810676.md)
---

# Novartis Expands Pipeline With $2 Billion Biotech Deal

Novartis (NVS, Financials) agreed to buy Excellergy, a biotech company located in the U.S., for up to $2 billion. This is part of a string of recent investments the company has made to grow its medication pipeline.

There will be upfront and milestone payments as part of the deal. The deal is anticipated to finalize in the second half of 2026, but only if all the necessary clearances are received.

The main goal of the acquisition is to improve Novartis' position in immunology, especially when it comes to treating food allergies. Excellergy's main medication candidate, Exl-111, is meant to help people with allergies feel better sooner. This might open up more treatment choices in a sector that is increasing.

The move comes barely a week after Novartis disclosed that it will pay up to $3 billion for a breast cancer treatment candidate from a U.S. biotech startup. The investments are part of a bigger plan to expand its pipeline by buying specific biotech companies.

Novartis has also been putting more money into the US, promising around $23 billion over several years to build more research and production facilities.

As the business builds its portfolio, investors will keep an eye on how these purchases lead to clinical success and long-term revenue growth.

### Related Stocks

- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [LYEL.US](https://longbridge.com/en/quote/LYEL.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference](https://longbridge.com/en/news/286652404.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)
- [Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal](https://longbridge.com/en/news/286352725.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)